Diana Brainard, AlloVir CEO
AlloVir unwraps PhII data of cell therapy in expanded transplant indication, leaves trial plans up in the air
AlloVir said its off-the-shelf cell therapy reduced the viral load of BK virus in a greater percentage of kidney transplant recipients compared to placebo in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.